--- title: "Alphamab Oncology (9966) stock: news and investor profile" url: "https://aibio.space/companies/alphamab-oncology/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Alphamab Oncology (HKEX: 9966), China. The directory classifies it as Biotechnology. Listing facts, related biotech companies and news on aibio.space." --- 9966 Alphamab Oncology HKEX · China # Alphamab Oncology (9966) news Alphamab Oncology is a public biotech or pharmaceutical company listed on HKEX under the ticker 9966, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Alphamab Oncology news We have not published a story on Alphamab Oncology yet. When there is news, it will appear here. ## Alphamab Oncology at a glance - **Ticker**: 9966 - **Listing**: HKEX - **Country**: China ### Related companies - [3SBio](https://aibio.space/companies/3sbio/) HKEX: 1530 - [Beijing SL Pharmaceutical Co.](https://aibio.space/companies/beijing-sl-pharmaceutical/) SZSE: 002038 - [Walvax Biotechnology Co.](https://aibio.space/companies/walvax-biotechnology/) SZSE: 300142 - [Medtide](https://aibio.space/companies/medtide/) HKEX: 3880 - [Guangdong Vtr Bio-Tech Co.](https://aibio.space/companies/guangdong-vtr-bio-tech/) SZSE: 300381 - [Jiangsu gdk Biotechnology Co.](https://aibio.space/companies/jiangsu-gdk-biotechnology/) SSE: 688670 - [Fujian Haixi Pharmaceuticals Co.](https://aibio.space/companies/fujian-haixi-pharmaceuticals/) HKEX: 2637 - [Shanghai Serum Bio-Technology Co.](https://aibio.space/companies/shanghai-serum-bio-technology/) SSE: 688163 ### Also on HKEX - [China Medical System Holdings](https://aibio.space/companies/china-medical-system/) 867 - [China Shineway Pharmaceutical Group](https://aibio.space/companies/china-shineway-pharmaceutical/) 2877 - [Everest Medicines](https://aibio.space/companies/everest-medicines/) 1952 - [Shenzhen Neptunus Interlong Bio-Technique Co.](https://aibio.space/companies/shenzhen-neptunus-interlong-bio-technique/) 8329 - [Abbisko Cayman](https://aibio.space/companies/abbisko-cayman/) 2256 - [Genfleet Therapeutics (Shanghai)](https://aibio.space/companies/genfleet-therapeutics-shanghai/) 2595 ## Questions about Alphamab Oncology What is the ticker symbol of Alphamab Oncology? Alphamab Oncology trades under the ticker 9966 on HKEX. Where is Alphamab Oncology listed? Alphamab Oncology is listed on HKEX. Our directory also records these other listings: GETTEX:3NK. Which country or territory is Alphamab Oncology listed under? Our directory records Alphamab Oncology under China. What does Alphamab Oncology do? Our directory classifies Alphamab Oncology as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Alphamab Oncology? The ISIN recorded for Alphamab Oncology is KYG0330A1013. Does aibio.space cover Alphamab Oncology? aibio.space lists Alphamab Oncology among 2,820 public biotech companies and publishes its news here as stories appear. Which companies are similar to Alphamab Oncology? Companies in our directory listed in the same country and business area as Alphamab Oncology: 3SBio, Beijing SL Pharmaceutical Co., Walvax Biotechnology Co., Medtide, Guangdong Vtr Bio-Tech Co., Jiangsu gdk Biotechnology Co.. ## Investor discussion: Alphamab Oncology Members talk about Alphamab Oncology (9966). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Alphamab Oncology, newest first. Each line links the filing it comes from. 1. 2026-10-23 Mergers Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION - EXERCISE OF WARRANT TO SUBSCRIBE FOR PREFERRED STOCK OF PATHOS AI, INC.. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1023/2026102301523.pdf) 2. 2026-05-20 Financings Share or debt issue: (1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES (INCLUDING RESELL OR TRANSFER TREASURY SHARES); (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0520/2026052000298.pdf) 3. 2025-05-20 Financings Share or debt issue: (1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES (INCLUDING RESELL OR TRANSFER TREASURY SHARES); (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING. [Source](https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0520/2025052000245.pdf) ## Press releases Headlines of Alphamab Oncology's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-26 HKEXnews [VOLUNTARY ANNOUNCEMENT - LATEST RESEARCH UPDATES OF JSKN003 PRESENTED AT THE 2026 ESMO CONGRESS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1026/2026102600963.pdf) 2. 2026-10-26 HKEXnews [VOLUNTARY ANNOUNCEMENT - RESULTS OF A PHASE I/II CLINICAL STUDY OF JSKN033 IN PATIENTS WITH CC FOLLOWING FAILURE OF STANDARD TREATMENT WERE PRESENTED AT THE 2026 ESMO CONGRESS AS A RAPID ORAL PRESENTATION](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1026/2026102600207.pdf) 3. 2026-10-26 HKEXnews [VOLUNTARY ANNOUNCEMENT - LATEST RESEARCH RESULTS OF TWO PHASE III CLINICAL STUDIES OF ANBENITAMAB (KN026) WERE PRESENTED AT THE 2026 ESMO CONGRESS AS LBA ORAL PRESENTATIONS](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1026/2026102600205.pdf) 4. 2026-10-23 HKEXnews [DISCLOSEABLE TRANSACTION - EXERCISE OF WARRANT TO SUBSCRIBE FOR PREFERRED STOCK OF PATHOS AI, INC.](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1023/2026102301523.pdf) 5. 2026-08-28 HKEXnews [VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0828/2026082803310.pdf) 6. 2026-08-27 HKEXnews [INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0827/2026082702013.pdf) 7. 2026-08-18 HKEXnews [VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NDA FOR ANBENITAMAB (KN026) AS FIRST-LINE TREATMENT FOR HER2-POSITIVE ADVANCED BREAST CANCER BY THE NMPA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0818/2026081801168.pdf) 8. 2026-08-04 HKEXnews [VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NDA FOR ANBENITAMAB (KN026) AS NEOADJUVANT TREATMENT FOR HER2+ BREAST CANCER BY THE NMPA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0804/2026080401576.pdf) 9. 2026-08-04 HKEXnews [VOLUNTARY ANNOUNCEMENT - TRANSACTIONS WITH PATHOS AI FOR JSKN016](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0804/2026080400073.pdf) 10. 2026-08-03 HKEXnews [VOLUNTARY ANNOUNCEMENT - APPROVAL FROM CDE FOR JSKN033 TO INITIATE A PHASE III CLINICAL STUDY FOR THE TREATMENT OF CERVICAL CANCER](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0803/2026080303971.pdf) 11. 2026-07-14 HKEXnews [VOLUNTARY ANNOUNCEMENT - ANBENITAMAB (KN026) WAS AGAIN GRANTED BREAKTHROUGH THERAPY DESIGNATION BY THE NMPA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0714/2026071400904.pdf) 12. 2026-06-12 HKEXnews [POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 12, 2026](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0612/2026061201456.pdf) 13. 2026-06-10 HKEXnews [VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) AS FIRST-LINE TREATMENT FOR HER2+ ADVANCED BREAST CANCER MET PRIMARY ENDPOINT](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0610/2026061001234.pdf) 14. 2026-06-05 HKEXnews [VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR AND MANAGEMENT](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0605/2026060500115.pdf) 15. 2026-06-02 HKEXnews [VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES OF JSKN016 FOR PRESENTATION AT 2026 ASCO ANNUAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0602/2026060200035.pdf) 16. 2026-06-01 HKEXnews [VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) FOR NEOADJUVANT TREATMENT OF BC WERE PRESENTED AT LBA ORAL PRESENTATION SESSION OF 2026 ASCO ANNUAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0601/2026060100049.pdf) 17. 2026-05-29 HKEXnews [INSIDE INFORMATION ANNOUNCEMENT - ANBENITAMAB INJECTION OBTAINED MARKETING APPROVAL FROM THE NMPA](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0529/2026052901141.pdf) 18. 2026-05-20 HKEXnews [NOTICE OF ANNUAL GENERAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0520/2026052000310.pdf) 19. 2026-05-20 HKEXnews [(1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES (INCLUDING RESELL OR TRANSFER TREASURY SHARES); (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0520/2026052000298.pdf) 20. 2026-05-13 HKEXnews [VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE II CLINICAL STUDY OF JSKN033 AS FIRST-LINE TREATMENT OF ADVANCED CERVICAL CANCER](https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0513/2026051300091.pdf) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open HKEX:9966 on TradingView](https://www.tradingview.com/symbols/HKEX-9966/). ## Listing details Alphamab Oncology is a public biotech or pharmaceutical company listed on HKEX under the ticker 9966, recorded under China. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Alphamab Oncology - **Ticker**: 9966 - **Listing**: HKEX - **Country or territory**: China - **Business scope**: Biotechnology - **ISIN**: KYG0330A1013 - **Other listed symbols**: GETTEX:3NK - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/HKEX-9966/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/alphamab-oncology/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Alphamab Oncology (9966) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/alphamab-oncology/